Cancer of the head and neck area

  1. A double-blind, randomized , two-arm phase 2 study of nivolumab in combination with ipilimumab versus nivolumab in combination with ipilimumab placebo in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    The purpose of the study is to assess if a combination therapy of nivolumab and ipilimumab is effective, safe, and tolerable therapy for treatment of squamous epithelial cancer of the neck and head area.
    Primary researcher: Micaela Hernberg
 

 Contact Information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680